FULGENT GENETICS, INC. Increase (Decrease) in Contract with Customer, Liability
FULGENT GENETICS, INC. (FLGT) reported Increase (Decrease) in Contract with Customer, Liability of -$231.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-30
- FULGENT GENETICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $396.00K.
- FULGENT GENETICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$627.00K, a 207.73% decline year-over-year.
- FULGENT GENETICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $1.32M.
- FULGENT GENETICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$363.00K, a 262.78% decline year-over-year.
- FULGENT GENETICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $1.40M.
- FULGENT GENETICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$639.00K.
- FULGENT GENETICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$325.00K.
- FULGENT GENETICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$11.50M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$231.00K 10-Q · filed 2026-07-30 | $1.09M derived: sum of 3 quarters · filed 2026-07-30 | $731.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$627.00K 10-Q · filed 2026-05-01 | $698.00K derived: sum of 2 quarters · filed 2026-05-01 | $335.00K derived: sum of 3 quarters · filed 2026-05-01 | $191.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $962.00K derived: sum of 2 quarters · filed 2026-02-27 | $818.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.40M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$363.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$507.00K derived: sum of 2 quarters · filed 2026-07-30 | $75.00K 10-Q · filed 2025-11-07 | -$657.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $438.00K 10-Q · filed 2026-07-30 | -$294.00K derived: sum of 3 quarters · filed 2026-07-30 | -$71.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $582.00K 10-Q · filed 2026-05-01 | -$150.00K derived: sum of 2 quarters · filed 2026-05-01 | $73.00K derived: sum of 3 quarters · filed 2026-05-01 | $54.00K derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | -$732.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$509.00K derived: sum of 2 quarters · filed 2026-02-27 | -$528.00K derived: sum of 3 quarters · filed 2026-02-27 | -$639.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $223.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $204.00K derived: sum of 2 quarters · filed 2025-11-07 | $93.00K 10-Q · filed 2025-11-07 | $381.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$130.00K 10-Q · filed 2025-08-01 | $158.00K derived: sum of 3 quarters · filed 2026-02-27 | $143.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$111.00K 10-Q · filed 2025-05-02 | $177.00K derived: sum of 2 quarters · filed 2026-02-27 | $162.00K derived: sum of 3 quarters · filed 2026-02-27 | |
| 2023-12-31 | $288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $273.00K derived: sum of 2 quarters · filed 2026-02-27 | -$325.00K 10-K · filed 2026-02-27 | |
| 2023-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$613.00K 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | -$598.00K 10-Q · filed 2024-08-02 | |||
| 2022-12-31 | -$11.50M 10-K · filed 2025-02-28 | |||
| 2021-09-30 | $965.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$6.08M derived: sum of 2 quarters · filed 2021-11-09 | -$18.70M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$7.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$19.66M 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | -$12.62M 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |